Irg1/Itaconate Inhibits Microglial Senescence-Like Transition By Modulating Mitochondrial Dynamics Through Rhoa Alkylation In Subarachnoid Hemorrhage
Brain hemorrhages, particularly subarachnoid hemorrhage (SAH), can lead to severe brain injury, and aging is a significant factor that worsens the prognosis. This new research sheds light on a crucial protective mechanism that often falters with age. It focuses on specialized immune cells in the brain, called microglia, which can enter a harmful “senescence-like” state—essentially, they start acting old and dysfunctional—after a hemorrhage, releasing substances that further damage the brain.
The study found that a molecule called itaconate, produced by a gene known as IRG1, acts as a natural defense against this microglial aging. In younger individuals, the body naturally ramps up IRG1 and itaconate production in response to the stress of a hemorrhage, helping to protect the brain. However, in older individuals, this protective response is significantly weaker.
When the IRG1-itaconate pathway is deficient, microglia experience excessive fragmentation of their mitochondria—the powerhouses of the cell—leading to dysfunction. The researchers discovered that itaconate directly modifies a protein called RhoA. This modification prevents RhoA from activating another protein, Drp1, which is responsible for mitochondrial fragmentation. By stopping this process, itaconate helps maintain healthy mitochondrial function and prevents microglia from becoming senescent.
Importantly, treating affected cells with a derivative of itaconate not only restored healthy mitochondrial activity but also reduced microglial senescence and improved neurological outcomes. These findings reveal a novel “metabolic-mitochondrial checkpoint” involving the IRG1/itaconate-RhoA-Drp1 pathway, suggesting that boosting this natural defense mechanism could be a promising strategy to combat age-related neuroinflammation and improve recovery after subarachnoid hemorrhage.
Source: link to paper